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www.cdatm.orgAbstractObjective: Previous studies have revealed inconsistent results regarding the association between occult hepatitis B virus (HBV)
infection and chronic kidney disease (CKD). Therefore, we conducted a prospective cohort study to evaluate the association be-
tween occult HBV infection and CKD.
Methods: A total of 4329 adults, aged 46.2 ± 13.7 years, without CKD at baseline were enrolled while undergoing physical
examinations. Occult HBV infection was defined as seropositivity for antibody to HBV core antigen. CKDwas defined as decreased
estimated glomerular filtration rate (eGFR < 60 ml$min1$1.73 m2) or presence of proteinuria 1þ, assessed using a repeated
dipstick method. eGFR was computed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Results: The prevalence of occult HBV infection was 8.1% (352/4329). During 5 years of follow-up, 165 patients (3.8%)
developed CKD. Univariate Logistic regression analysis showed that occult HBV infection was positively associated with
decreased eGFR, with an odds ratio (OR) of 2.15 (95% confidence interval (CI): 1.05e4.11). In contrast, occult HBV infection was
not associated with either proteinuria or CKD (P > 0.05). After adjustment for potential confounders in the multivariate Logistic
regression analysis, age, hypertension, diabetes, and the highest quartile of uric acid were associated with CKD, with ORs of 1.04
(95% CI: 1.02e1.05), 2.1 (95% CI: 1.46e3.01), 2.02 (95% CI: 1.36e2.99), and 1.86 (95% CI: 1.17e2.95), respectively. However,
occult HBV infection was not associated with CKD, with an OR of 1.12 (95% CI: 0.65e1.95).
Conclusions: This study did not find an association between occult HBV infection and CKD. However, high-risk patients infected
with HBV should still be targeted for monitoring for the development of CKD.
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Chronic kidney disease (CKD) has become a major
worldwide public health problem over the past few de-
cades, with increasing incidence and prevalence, high
management costs, and poor treatment outcomes.1,2 A
recent national survey in China has indicated that the
prevalence of CKD is 10.8%, and the number of patients
with CKD is estimated to be 119.5 million.3 The rapid
increases in diabetes and hypertension are predicted to
drive epidemics ofCKD.However, this increased risk for
CKD cannot be fully explained by traditional factors,
including age, hypertension, diabetes, and dyslipidemia.
Hepatitis B virus (HBV) infection, a common cause of
liver disease and liver cancer, infects more than 400
million people worldwide.4 The prevalence of HBV
infection varies significantly in different geographic
areas of the world. In the mainland of China, the preva-
lence of seropositivity forHBV surface antigen (HBsAg)
was found to be 7.18% and the number of patients with
chronic HBV infection is estimated at 93 million.5
It has been known for the past few decades that
chronic HBV infection is associated with renal dis-
ease.6,7 Renal involvement is among the most common
extrahepatic manifestations and is usually associated
with membranous and membranoproliferative glomer-
ulonephritis.8e10 The overall prevalence of HBV
infection associated with nephropathy is not known. A
study reported that about 3% of HBV-infected patients
had glomerulonephritis.11 A cohort study of Chinese
subjects with type 2 diabetes reported that chronic HBV
infection was associated with an increased risk of end-
stage renal disease (ESRD).12 In Taiwan of China, a
cohort study also suggested that chronic HBV infection
increased the risk of ESRD.13 However, several cross-
sectional observational studies have shown inconsis-
tent results regarding the association between HBV
infection and CKD. They found that HBV infection was
not associated with CKD in Chinese14e16 and Japa-
nese17 adults. It has been observed that HBV infection is
associated with nephropathy18, but the association be-
tween occult HBV infection and CKD remains unclear.
To help clarify this problem,we conducted a prospective
cohort study to evaluate the association between occult
HBV infection and CKD.
Methods
Study population
A total of 4874 adults who consecutively visited the
Health Checkup Clinic in a large tertiary-careuniversity hospital were enrolled from April 2008 to
December 2008. Those participants came from all over
Jinan to receive a regular paid health examination. Of
these, 48 participants with proteinuria, 151 with he-
maturia, and 62 with decreased eGFR at baseline were
excluded. Thus, 4613 participants were followed for 5
years; 198 were lost to follow-up. Patients with
cirrhosis, hepatic carcinoma, HIV infection, and Hep-
atitis C virus infection were not included. We also
excluded subjects who took nucleoside or nucleotide
analogues (lamivudine, adefovir, entecavir, telbivu-
dine) before the CKD event occurred. The ethics
committee of Qianfoshan Hospital approved the study.
All participants gave written informed consent prior to
data collection.
Blood biochemistry measurements and biometric parame-
ters at baseline
Blood was collected by venipuncture after an
overnight fast of at least 10 h. Routine serum and
urinary chemistry analyses were performed by stan-
dard automated techniques. Estimated glomerular
filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-
EPI) two-level race equation.19,20 Serum creatinine
level was measured using the Roche enzymatic method
on an automatic biochemistry analyzer (Roche-Hitachi
P-Module instrument with Roche Creatininase Plus
assay, Hoffman-La Roche, Basel, Switzerland). Pro-
teinuria was measured on a morning urine sample by
using a repeated dipstick method. Participants with
pyuria were excluded from the analysis of proteinuria
due to possible urinary tract infection. Menstruating
women were asked to delay the urine test until 3 days
after menstruation. A dipstick result of trace or more
urine protein was defined as proteinuria.
Serum sample was tested for the presence of HBV
surface antigen (HBsAg) and antibodies to HBV core
antigen (anti-HBc) and HBV e antigen (anti-HBe) by
using enzyme-linked immunosorbent assay (Roche
Diagnostics, Basel, Switzerland). Occult HBV infec-
tion was defined as seropositive for antibody to HBV
core antigen. Fasting blood glucose, alanine trans-
aminase (ALT), aspartate aminotransferase (AST),
hemoglobin, serum uric acid (UA), serum total
cholesterol, low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol, and tri-
glyceride levels were also measured using an auto-
matic biochemistry analyzer. Total plasma alkaline
phosphatase (ALP) level was assessed using colori-
metric determination.
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history (e.g., hypertension and diabetes), were obtained
by means of a questionnaire. The body mass index
(BMI) was calculated as weight (in kilograms) divided
by height squared (in square meters). Diabetes was
defined as fasting blood glucose level 7.0 mmol/L,
the use of hypoglycemic agents, or self-reported his-
tory of diabetes. Blood pressure was measured using a
sphygmomanometer, and 3 measurements were ob-
tained at 5-min intervals. The mean of the 3 readings
was calculated, unless the difference between the
readings was greater than 10 mmHg, in which case the
mean of the 2 closest measurements was used. Hy-
pertension was defined as systolic blood pressure of
more than 140 mmHg or diastolic blood pressure of
more than 90 mmHg, or both, or the use of antihy-
pertensive medication.
All of the investigators and staff members
completed a training program to learn the methods and
procedures of the study.
Outcomes
The eGFR was reevaluated using the same strategy
after 5 years of follow-up. CKD was defined as
decreased eGFR <60 ml$min1$1.73 m2 or presence
of proteinuria (urine protein 1þ).21 A total of 86
participants were excluded from the analysis because
of insufficient blood or urine results, and 4329 partic-
ipants were included in the final analysis.
Statistical analysis
Data were presented as proportions for categorical
variables and mean ± standard deviation (SD) or me-
dian [interquartile range (IQR)] for continuous vari-
ables. The significance of the differences in continuous
variables between groups was tested using one-way
analysis of variance. The difference in the distribu-
tion of categorical variables was tested using the Chi-
square or Fisher's exact test. Univariate and multivar-
iate Logistic regression analysis were used to estimate
the association between HBV infection and CKD. In-
dependent variables included age (continuous), gender,
hypertension (yes/no), diabetes (yes/no), BMI
(continuous), chronic carrier (yes/no) or occult HBV
infection (yes/no), and levels of serum UA, total
cholesterol, triglycerides, LDL cholesterol, and HDL
cholesterol. Serum UA levels were analyzed in gender-
specific quartiles. The 25th, 50th, and 75th percentiles
for males were 300.0, 344.0, and 386.0 mmol/L,
respectively. The 25th, 50th, and 75th percentiles forfemales were 224.0, 255.0, and 293.0 mmol/L,
respectively.
Crude and adjusted odds ratios (ORs) with 95%
confidence interval (CI) were reported. All analyses
were performed using SPSS statistical package,
version 16.0 (SPSS Inc, Chicago, IL, USA). All
P-values were two-tailed. A P value of less than 0.05
was considered statistically significant.
Results
Among 4329 participants in the study, the mean age
was 46.2 ± 13.7 years (range 18e84 years), and 67.2%
(2907/4329) were men. The prevalence of occult HBV
infection was 8.1% (352/4329). The mean eGFR was
(97.0 ± 14.6) ml$min1$1.73 m2. Baseline charac-
teristics of the participants stratified according to HBV
status are shown in Table 1.
During 5 years of follow-up, the median change in
eGFR was 2.4 ml$min1$1.73 m2 (IQR,
7.4e2.9 ml$min1$1.73 m2). A total of 165 pa-
tients (3.8%) developed CKD, with median change in
eGFR of 5.3 ml$min1$1.73 m2 (IQR,
14.0e4.0 ml$min1$1.73 m2). The incidence of
kidney damage according to HBV status is shown in
Table 2. The percentages of decreased eGFR and
incidence of CKD in patients with occult HBV infec-
tion were higher than in participants with no exposure
to HBV, i.e., 2.6% vs. 1.2% (P ¼ 0.04) and 4.8% vs.
3.7% (P ¼ 0.31), respectively.
We analyzed the ORs of variables associated with
CKD. Univariate Logistic regression analysis showed
that occult HBV infection was positively associated
with decreased eGFR, with an OR of 2.15 (95% CI:
1.05e4.11). In contrast, occult HBV infection was not
associated with either proteinuria or CKD (P > 0.05)
(Table 3). After adjustment for potential confounders
in the multivariate Logistic regression analysis, age,
hypertension, diabetes and the highest quartile of UA
were associated with CKD, with ORs of 1.04 (95% CI:
1.02e1.05), 2.1 (95% CI: 1.46e3.01), 2.02 (95% CI:
1.36e2.99), and 1.86 (95% CI: 1.17e2.95), respec-
tively. However, occult HBV infection was not asso-
ciated with CKD, with an OR of 1.12 (95% CI:
0.65e1.95) (Table 4).
Discussion
Although renal involvement in HBV infection was
first reported decades ago6,7, knowledge of the asso-
ciation between occult HBV infection and CKD re-
mains limited. The current cohort study analyzed data
Table 1
Baseline clinical characteristics of participants, stratified according to hepatitis B virus infection status.
Characteristics Total (n ¼ 4329) No exposure
(n ¼ 3977)
Occult HBV infection
(n ¼ 352)
P
Age, years 46.2 ± 13.7 46.0 ± 13.6 48.9 ± 14.7 0.00
Male, n (%) 2907 (67.2) 2672 (67.2) 235 (66.8) 0.86
BMI, kg/m2 24.8 ± 3.4 24.8 ± 3.4 24.8 ± 3.4 0.97
ALT, U/L 24.8 ± 16.5 24.5 ± 15.1 27.9 ± 27.5 0.00
AST, U/L 21.9 ± 9.2 21.6 ± 7.7 24.8 ± 19.4 0.00
Alkaline phosphatase, U/L 60.4 ± 16.9 60.2 ± 16.9 62.0 ± 16.2 0.06
Blood glucose, mmol/L 6.0 ± 1.2 6.0 ± 1.2 6.0 ± 1.2 0.54
SBP, mmHg 123.8 ± 18.4 123.6 ± 18.3 126.2 ± 19.3 0.01
DBP, mmHg 78.8 ± 12.4 78.6 ± 11.8 79.6 ± 12.1 0.13
Hypertension, n (%) 927 (21.4) 839 (21.2) 88 (25.1) 0.09
Diabetes, n (%) 454 (10.5) 418 (10.5) 36 (10.2) 0.93
Hemoglobin, g/L 142.5 ± 14.5 142.3 ± 14.6 143.7 ± 13.5 0.17
BUN, mmol/L 4.8 ± 1.2 4.8 ± 1.2 5.0 ± 1.3 0.03
Serum creatinine, mmol/L 76.9 ± 12.6 76.8 ± 12.6 77.8 ± 12.8 0.15
UA, mmol/L 318.9 ± 75.5 319.0 ± 75.9 317.4 ± 71.0 0.71
Total cholesterol, mmol/L 5.2 ± 0.9 5.2 ± 0.9 5.1 ± 0.9 0.1
Triglycerides, mmol/L 1.5 ± 1.2 1.5 ± 1.2 1.3 ± 1.1 0.09
LDL cholesterol, mmol/L 3.2 ± 0.6 3.2 ± 0.6 3.1 ± 0.6 0.11
HDL cholesterol, mmol/L 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.3 0.71
eGFR ml$min1$1.73 m2 97.0 ± 14.6 97.3 ± 14.4 94.3 ± 15.9 0.00
Values are expressed as mean ± SD or n (%). HBV: hepatitis B virus; BMI: body mass index; ALT: alanine transaminase; AST: aspartate
aminotransferase; SBP: systolic blood pressure; DBP: diastolic blood pressure; BUN: blood urea nitrogen; UA: uric acid; LDL: low-density li-
poprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular filtration rate; SD: standard deviation.
Table 2
Incidence of kidney damage according to hepatitis B virus infection status.
Items eGFR, ml$min1$1.73 m2 Change of eGFR,
ml$min1$1.73 m2
Proteinuria, n (%) deGFR, n (%) CKD, n (%)
No exposure 94.9 ± 14.4 2.4 ± 9.4 106 (2.7) 48 (1.2) 148 (3.7)
Occult HBV
infection
93.3 ± 15.5 1.0 ± 10.5 9 (2.6) 9 (2.6) 17 (4.8)
P 0.04 0.01 1.00 0.04 0.31
Values are expressed as mean ± SD or n (%). eGFR: estimated glomerular filtration rate; deGFR: decreased estimated glomerular filtration rate;
CKD: chronic kidney disease; HBV: hepatitis B virus.
Table 3
Univariate Logistic regression analysis for hepatitis B virus infection
status with indicators of kidney damage.
Items deGFR
[OR (95% CI)]
Proteinuria
[OR (95% CI)]
CKD
[OR (95% CI)]
No exposure Reference Reference Reference
Occult HBV
infection
2.15 (1.05e4.11) 0.96 (0.48e1.91) 1.31 (0.79e2.2)
P 0.04 0.90 0.30
deGFR: decreased estimated glomerular filtration rate;OR: odds ratio;
CI: confidence interval; CKD: chronic kidney disease; HBV: hepatitis
B virus.
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screening and were followed up for 5 years, and found
that occult HBV infection was not independently
associated with an increased risk of CKD.HBV infection associated with membranous
nephrology is well established, and there also have been
reports of HBVassociation with membranoproliferative
or proliferative glomerulonephritis.8e10 The association
between chronic HBV infection and the development
CKD remains controversial. A 2-year multicenter cross-
sectional study reported that CKD was highly prevalent
in treatment-naive patients with chronic HBV infec-
tion.22 A cross-sectional study reported that HBV was
associated with CKD in 416 HBV-infected adults23;
however, another study by the same research group re-
ported that HBV was not associated with CKD or pro-
teinuria in 5424 HBV-infected adults.16 Similarly, a
cross-sectional study of 328 HBV-infected adults in
China reported that HBV was not associated with CKD
or albuminuria.24 On the other hand, a cross-sectional
Japanese study of 130 HBV-infected adults showed
Table 4
Multivariate Logistic regression analysis for associations with CKD.
Variables Multivariable adjusted ORa
(95% CI)
P
Age 1.04 (1.02e1.05) 0.00
Gender 0.67 (0.44e1.02) 0.06
Hypertension 2.1 (1.46e3.01) 0.00
Diabetes 2.02 (1.36e2.99) 0.00
BMI 0.99 (0.94e1.05) 0.88
UA (gender-specific quartiles)b
Quartile 1 Reference e
Quartile 2 0.95 (0.57e1.58) 0.84
Quartile 3 0.99 (0.59e1.66) 0.98
Quartile 4 1.86 (1.17e2.95) 0.01
Occult HBV infection 1.12 (0.65e1.95) 0.68
Total cholesterol 1.3 (0.83e2.04) 0.25
Triglycerides 1.05 (0.88e1.26) 0.58
LDL cholesterol 0.61 (0.37e1.01) 0.05
HDL cholesterol 0.8 (0.39e1.61) 0.53
CKD: chronic kidney disease;OR: odds ratio; CI: confidence interval;
BMI: body mass index; UA: uric acid; LDL: low-density lipoprotein;
HDL: high-density lipoprotein.
a Adjusted for age, gender, hypertension, diabetes, BMI, UA, pre-
vious exposure, total cholesterol, triglycerides, LDL cholesterol, and
HDL cholesterol.
b The 25th, 50th, and 75th percentiles for males were 300.0, 344.0,
and 386.0 mmol/L, respectively. The 25th, 50th, and 75th percentiles
for females were 224.0, 255.0, and 293.0 mmol/L, respectively.
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inversely associated with CKD.15 A 13-year nationwide
cohort study of CKD risk among treatment-naive pa-
tients with chronic HBV showed that untreated chronic
HBV infection was associated with an increased risk of
CKD.25 The discrepancies among these studies may be
attributed to the differences among the specific pop-
ulations. The present study used a cohort design with a
large dataset, which afforded considerable statistical
power and allowed tracking of the incidence of CKD
events over 5 years, but we did not find that occult HBV
infection was associated with CKD.
The pathogenetic mechanisms by which individuals
with HBV infection may develop nephropathy are not
clearly defined. The most widely accepted mechanism
is the deposition of immune complexes of viral antigen
and host antibody.18 Experiments in animals by Ger-
muth et al26 demonstrated that when an animal was
exposed to a foreign antigen, nephritis developed,
depending on the circulation of different proportions of
antibodies and antigens. In the absence of antibodies,
with the antigen present only in the serum, there was
no nephritis. When the antigen persisted in the serum
with low levels of antibody, chronic nephritis with
subepithelial deposits developed. HBV infection is also
associated with increased insulin resistance15 andintensification of oxidative stress27, and these may
contribute to renal injury.28 Other research has revealed
that HBV infection increase apoptosis in renal tubular
cells via upregulation of Fas gene expression, and these
patients had a higher circulating level of transforming
growth factor-b, which is implicated in the potentiation
of apoptosis and renal fibrosis.29 In this study, the cu-
mulative incidence rate of CKD following occult HBV
infection was only 4.8%. This indicates that occult
HBV infection by itself is insufficient for the devel-
opment of nephropathy but requires interplay of ge-
netic and environmental factors in specifically
vulnerable individuals.18 Nevertheless, most adults
(30%e50%) with HBV-associated nephropathy prog-
ress to ESRD.30 It is estimated that 50 million new
cases of HBV infection are diagnosed annually, despite
a marked increase in vaccination rates.31 Therefore, it
is conceivable that the burden of CKD following HBV
infection is increasing.
This study has limitations. First, the effect of viral
load evaluated by HBV-DNA levels was not assessed.
Second, we only had 2 measurements of eGFR.
Although there may be variations in laboratory mea-
surements, this type of misclassification would tend to
bias our study toward not finding an association, and
may have underestimated the true association. Third,
we used a single morning spot urine sample to assess
microalbuminuria instead of timed urine collections.
Finally, since our study was observational, the possi-
bility of residual confounding by some unmeasured
covariate exists.
In conclusion, this study did not find that occult
HBV infection was associated with CKD. However,
high-risk patients infected with HBV should still be
targeted for monitoring for the development of CKD.
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